Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma

J Thorac Oncol. 2015 Apr;10(4):e21-2. doi: 10.1097/JTO.0000000000000449.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / enzymology
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Adenocarcinoma of Lung
  • Anaplastic Lymphoma Kinase
  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use*
  • Biomarkers, Tumor / metabolism
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Magnetic Resonance Imaging
  • Middle Aged
  • Radiotherapy, Adjuvant
  • Receptor Protein-Tyrosine Kinases / metabolism*
  • Tomography, X-Ray Computed

Substances

  • Angiogenesis Inhibitors
  • Biomarkers, Tumor
  • Bevacizumab
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases